MRK
Another day, another Keytruda headline
Merck dropped topline data from its Phase 3 KEYNOTE-C93 trial, and the big takeaway is simple: Keytruda outperformed platinum doublet chemotherapy in patients with mismatch repair-deficient advanced or recurrent endometrial cancer. That’s not just science-speak for fun — it’s the kind of result that can help keep one of pharma’s biggest money machines humming.
Why investors should care
The trial hit its primary progression-free survival endpoint, which means patients on Keytruda stayed longer without their cancer getting worse than those on chemo. Merck also said there was a trend toward better overall survival, though those data aren’t mature yet. Translation: promising, but not the final chapter.
More ammo for the blockbuster
The safety profile looked consistent with prior studies, and no new safety signals showed up — always a relief when you’re asking Wall Street to keep believing in a giant oncology franchise. Keytruda is already a monster brand, and every new win helps Merck defend the crown as competition keeps circling like it’s last call.
Big picture
Merck’s stock got a pop, and for good reason: more positive data can mean more label expansion, more time on the market, and more confidence that Keytruda can keep carrying the company’s growth story. In pharma, that’s about as close as you get to a perpetual motion machine.